Designation Allows for Expedited Review of Transcatheter Therapy Designed to Improve Left Ventricular Structure and Function in Heart Failure Patients with Reduced Ejection Fraction
Designation Allows for Expedited Review of Transcatheter Therapy Designed to Improve Left Ventricular Structure and Function in Heart Failure Patients with Reduced Ejection FractionSANTA CLARA, Calif. (BUSINESS WIRE) #accucinch Ancora Heart, Inc., a company developing a novel device-based therapy to address heart.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Ancora Heart Enrolls First Patient in the CORCINCH-HF Study
January 28, 2021 GMT
As the only completely transcatheter procedure to treat the enlarged left ventricle, the AccuCinch® Ventricular Restoration System is a fundamentally different and innovative device-based therapy designed to improve the structure and function of the heart and help bring relief to HF patients who remain symptomatic despite current guideline-directed medical care. (Graphic: Business Wire)
As the only completely transcatheter procedure to treat the enlarged left ventricle, the AccuCinch® Ventricular Restoration System is a fundamentally different and innovative device-based therapy designed to improve the structure and function of the heart and help bring relief to HF patients who remain symptomatic despite current guideline-directed medical care. (Graphic: Business Wire)